Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Graft Versus Host Disease (GVHD) Market

Graft Versus Host Disease (GVHD) Market Share

Report ID: GMI8768
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Graft Versus Host Disease Market Share

The GVHD industry exhibited high competitiveness with several players vying for prominence. Key competitors are utilizing diverse GVHD treatment portfolios to sustain market dominance, while others are providing specialized therapies. Competition pivoted on factors such as product efficacy, safety, regulatory approvals, and pricing, advancing innovation and collaborative efforts among industry stakeholders to drive advancements in the field.

Graft Versus Host Disease Market Companies

Prominent players operating in the graft versus host disease industry are as mentioned below:

Astellas Pharma Inc.
Bristol Myers Squibb
ElsaLys Biotech SA
Incyte Corporation
Johnson & Johnson Services, Inc.
Kiadis Pharma
Mallinckrodt Pharmaceuticals
Merck & Co., Inc.
Mesoblast Ltd.
Neovii Pharmaceuticals AG
Novartis AG
Pfizer Inc.
Sanofi
Soligenix

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Graft versus host disease (GVHD) industry size was USD 2.5 billion in 2023 and is expected to record USD 5.1 billion by 2032, due to the increasing prevalence of hematological disorders and malignancies necessitating hematopoietic stem cell transplantation (HSCT).

The hospital pharmacies distribution channel segment recorded 48.4% revenue share in 2023 and is expected to reach USD 2.4 billion by end of 2032, due to their pivotal role in providing immediate access to specialized medications and therapies.

North America graft versus host disease industry size was anticipated to reach USD 2.1 billion by 2032, attributed to its robust healthcare infrastructure, growing R&D activities, and escalating transplant rates.

Some of the leading GVHD firms are Astellas Pharma Inc., Bristol Myers Squibb, ElsaLys Biotech SA, Incyte Corporation, Johnson & Johnson Services, Inc., Kiadis Pharma, Mallinckrodt Pharmaceuticals, Merck & Co., Inc., and Mesoblast Ltd.